D-Captopril

D-Captopril

SCHEMBL678794

CC(CS)C(=O)N1CCCC1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of D-Captopril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACE known ✓ P12821 7/20 1.00
REN P00797 4/20 1.00
KDM4E B2RXH2 1/20 1.00
F2 P00734 1/20 1.00
LMNA P02545 1/20 1.00
LTA4H P09960 1/20 1.00
MAPT P10636 1/20 1.00
PEPD P12955 1/20 1.00
ALOX15 P16050 1/20 1.00
PTGS1 P23219 1/20 1.00
HTR2A P28223 1/20 1.00
PTGS2 P35354 1/20 1.00
HRH1 P35367 1/20 1.00
THPO P40225 1/20 1.00
PMP22 Q01453 1/20 1.00
HSD17B10 Q99714 1/20 1.00
ACE2 Q9BYF1 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Captopril SCHEMBL7983782 1.00 ACE (1.00) ACERENKDM4EF2LMNA
D-Captopril SCHEMBL675797 1.00 ACE (1.00) ACERENKDM4EF2LMNA
D-Captopril SCHEMBL2444049 1.00 ACE (1.00) ACERENKDM4EF2LMNA
D-Captopril SCHEMBL1913521 1.00 ACE (1.00) ACERENKDM4EF2LMNA
Captopril SCHEMBL4 1.00 ACE (1.00) ACERENKDM4EF2LMNA
D-Captopril SCHEMBL2422871 1.00 ACE (1.00) ACERENKDM4EF2LMNA
D-Captopril SCHEMBL2444053 1.00 ACE (1.00) ACERENKDM4EF2LMNA
Captopril SCHEMBL2786691 1.00 ACE (1.00) ACERENKDM4EF2LMNA
Captopril SCHEMBL5556542 0.98 ACE (0.97) ACERENKDM4EF2LMNA
Captopril SCHEMBL2489188 0.98 ACE (0.97) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030100770-A1 Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) PENTRAXIN THERAPEUTICS LTD. (GB) 2003-05-29 US claimed
EP-0915088-A1 D-Proline derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-05-12 EP claimed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
US-20230172885-A1 THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-06-08 US disclosed
US-20230172885-A1 THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-06-08 US disclosed
CN-114634891-B Bacillus bailii ZH3 and application thereof 厦门萤星海科技有限公司 2023-06-02 CN disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 US disclosed
WO-2023284611-A1 ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF THE UNIVERSITY OF HONG KONG (CN) 2023-01-19 WO disclosed
CN-114634891-A Bacillus belgii ZH3 and application thereof 厦门萤星海科技有限公司 2022-06-17 CN disclosed
US-6103910-A FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE HOFFMANN-LA ROCHE INC. (US) 2000-08-15 US disclosed
EP-0915088-A1 D-Proline derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-05-12 EP disclosed
US-5571834-A HYPOTENSIVE AGENTS ZAMBON GROUP S.P.A. (IT) 1996-11-05 US disclosed
US-5304570-A Ibopamine or salt and enzyme inhibitor (S,S),-N-(3-(4-methoxybenzoylthio)-2-methyl-propionyl)-proline) ZAMBON GROUP S.P.A. (IT) 1994-04-19 US disclosed
EP-0351017-B1 Pharmaceutical composition useful for the treatment of cardiovascular diseases ZAMBON SPA (IT) 1994-01-19 EP disclosed
EP-0351017-A2 Pharmaceutical composition useful for the treatment of cardiovascular diseases ZAMBON GROUP S.p.A. (IT) 1990-01-17 EP disclosed
EP-0037231-B1 SUBSTITUTED ACYL DERIVATIVES OF OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACIDS WARNER-LAMBERT COMPANY (US) 1987-01-28 EP disclosed
US-4442090-A ACYLATED AMINO ACID KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1984-04-10 US disclosed
US-4105776-A ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100770-A1 Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) PSEN1, PSEN2, IAPP ACE 1460/4885REN 166/4885KDM4E 1764/4885
US-20230172885-A1 THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS CTH, SARS1, CBS ACE 4/4885REN 392/4885KDM4E 3990/4885
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 ACE 380/4885REN 1665/4885KDM4E 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.